Increasing evidence have demonstrated the potential of targeting CB1 as an anticancer strategy because of its pivotal role in cancer development and progression [33, 34] and accumulating studies have also verified the inhibitory effect of rimonabant in various malignancies, including breast cancer [35], colon cancer [36, 37], and fibrosarcoma [38]. The gene discussed is CNR1; the disease is fibrosarcoma.